Aslan to reduce headcount, operating costs to support upcoming milestones

Aslan Pharmaceuticals Ltd. (TPEx:6497; NASDAQ:ASLN) said late Tuesday it will reduce headcount by 30% and slash operating costs by 50%.

The restructuring will help support Aslan well into 2020 as it focuses operations on its existing clinical programs, co-founder and CEO Carl Firth told BioCentury. Aslan's operating expenses were $31 million for the first nine months of 2018. The company had $35 million in cash as of Sept. 30, 2018...